![Mitchell Shirvan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mitchell Shirvan
Directeur Général chez
D.H.S Medical Ltd.
Fortune : 16 523 $ au 31/07/2026
Profil
Mitchell Shirvan currently works at D.H.S Medical Ltd., as Chief Executive Officer, Silexion Therapeutics Corp., as Chief Scientific & Development Officer from 2024, and Silexion Therapeutics Ltd., as Chief Scientific & Development Officer from 2022.
Dr. Shirvan also formerly worked at Macrocure Ltd., as Chief Executive Officer from 2008 to 2012, Teva Pharmaceutical Industries Ltd., as Senior Director-Global Strategic Business from 1992 to 2008, and VYNE Pharmaceuticals Ltd., as Vice President-Innovation & Discovery from 2017 to 2019.
Dr. Shirvan received his Masters Business Admin degree from the University of Bradford and doctorate degree from The Hebrew University of Jerusalem.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
2,1 % | 11/06/2026 | 8 789 ( 2,1 % ) | 16 523 $ | 31/07/2026 |
Postes actifs de Mitchell Shirvan
| Sociétés | Poste | Début |
|---|---|---|
D.H.S Medical Ltd.
 D.H.S Medical Ltd. Packaged SoftwareTechnology Services Develops a platform technology for treating and monitoring heart failure | Directeur Général | - |
Silexion Therapeutics Ltd.
 Silexion Therapeutics Ltd. BiotechnologyHealth Technology Operates as aa clinical-stage oncology-focused biotechnology company | Directeur Technique/Scientifique/R&D | 01/04/2022 |
Anciens postes connus de Mitchell Shirvan
| Sociétés | Poste | Fin |
|---|---|---|
VYNE Pharmaceuticals Ltd.
 VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products for dermatology, gynecology, wounds and burns and ophthalmic disorders | Directeur Technique/Scientifique/R&D | 01/08/2017 |
| MACROCURE LTD | Directeur Général | 01/01/2012 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01/01/2008 |
Formation de Mitchell Shirvan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
62
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Teva Pharmaceutical Industries Ltd.
 Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products for dermatology, gynecology, wounds and burns and ophthalmic disorders | Health Technology |
University of Bradford
 University of Bradford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Macrocure Ltd.
 Macrocure Ltd. Medical SpecialtiesHealth Technology Develops a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers | Health Technology |
D.H.S Medical Ltd.
D.H.S Medical Ltd. Packaged SoftwareTechnology Services Develops a platform technology for treating and monitoring heart failure | Technology Services |
Silexion Therapeutics Ltd.
Silexion Therapeutics Ltd. BiotechnologyHealth Technology Operates as aa clinical-stage oncology-focused biotechnology company | Health Technology |
